Genetech

Personalized DNA testing company 23andMe is going public with a SPAC deal announced Thursday. The SPAC Deal: 23andMe is going public with VG Acquisition Corp (NYSE: VGAC), a SPAC from Virgin Group. The deal values 23andMe at $3.5 billion. A $250-million PIPE includes $25-million investments from...

"Paraskavedekatriaphobia" — Ever heard of it? This phobia concerns fear of Friday the 13th. The day has been considered unlucky since time immemorial. There have been different explanations for why the day is unlucky, although the oft-mentioned reason is Jesus being with 12 of his disciples (...

Following the FDA's December approval of Spinraza, Biogen Inc (NASDAQ: BIIB)'s commercial form of nusinersen for the treatment of spinal muscular atrophy, Cantor Fitzgerald analysts warned that the drug may provoke a now-latent debate on drug prices. "We wonder whether 2017 could start with a...

The biotech space is inherently fraught with risks, risks of failures in clinical trials, regulatory logjams, political policies hurting profits, just to name a few. Investment philosophy says high risks often correlate with high returns. However, the markets failed to reward these risky...